Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.
This latest generation of tools, called ExPERT, boasts new updated software, a touchscreen interface and other features that MaxCyte says represent a “significant improvement” to the user experience.
The combination of the new instruments, together with the launch of a new range of processing assemblies, will allow customers to use a single technology from early research through to clinical and commercial use.
“We are proud to announce the launch of our next-generation ExPERT brand of instruments,” said chief executive and president Doug Doerfler.
Executive vice president of global commercial operations, Brad Calvin, added: “The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies.
“Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies.”